An mRNA vaccine encoding the SARS-CoV-2 Omicron XBB.1.5 receptor-binding domain protects mice from the JN.1 variant

• Published in: EBioMedicine Vol. 117; p. 105794
• Main Authors: Uraki, Ryuta, Kiso, Maki, Ito, Mutsumi, Yamayoshi, Seiya, Halfmann, Peter, Jain, Shilpi, Suthar, Mehul S., Lopes, Tiago J.S., Jounai, Nao, Miyaji, Kazuki, Takeshita, Fumihiko, Kawaoka, Yoshihiro
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.07.2025; Elsevier
• Subjects: Advanced Basic Science; Animals; Antibodies, Neutralizing - immunology; Antibodies, Viral - immunology; COVID-19 - immunology; COVID-19 - prevention & control; COVID-19 - virology; COVID-19 Vaccines - administration & dosage; COVID-19 Vaccines - genetics; COVID-19 Vaccines - immunology; Female; Humans; Immunization, Secondary; Internal Medicine; LNP-mRNA-RBD; Mice; Mice, Inbred BALB C; Mouse model; mRNA Vaccines - immunology; Omicron JN.1 variant; RNA, Messenger - genetics; RNA, Messenger - immunology; SARS-CoV-2; SARS-CoV-2 - genetics; SARS-CoV-2 - immunology; Spike Glycoprotein, Coronavirus - chemistry; Spike Glycoprotein, Coronavirus - genetics; Spike Glycoprotein, Coronavirus - immunology; Vaccines, Synthetic - genetics; Vaccines, Synthetic - immunology; SARS-CoV-2; Mouse model; Omicron JN.1 variant; LNP-mRNA-RBD

The SARS-CoV-2 Omicron BA.2.86 variant and its descendant lineages, including JN.1, are rapidly spreading globally. We developed mRNA encoding the SARS-CoV-2 RBD derived from XBB.1.5 (XBB.1.5-type LNP-mRNA-RBD), in line with WHO recommendations. Many individuals have acquired immunity specific to th...